ACUTE TOXICITY OF EXTENDED FIELD INTENSITY MODULATED RADIOTHERAPY AND CONCURRENT CHEMOTHERAPY IN HIGH RISK CERVICAL CANCER PATIENTS

EVALUATION OF ACUTE TOXICITY OF EXTENDED FIELD INTENSITY MODULATED RADIOTHERAPY WITH CONCURRENT CISPLATIN IN CERVICAL CANCER PATIENTS WITH PELVIC LYMPH NODE METASTASIS.

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/01/011599

Enrollment

Registered

2018-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- carcinoma cervix

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Previously untreated, biopsy proven squamous cell carcinoma of cervix stage IB2-IIIB 2. Para aortic nodes negative and pelvic lymph node positive on FDG PET scans 3. Karnofsky performance scale > 70 (annexure-VII) 4. Pre treatment parameters :- a) Hemoglobin >10gm/dl b) TLC >4000/mm3 c) Platelets > 100000/mm3 d) Blood urea e) Serum creatinine f) Normal Chest X-ray 5. Patients willing to give informed consent and agreeing for follow up

Exclusion criteria

Exclusion criteria: 1. All post operative cases 2. History of prior pelvic radiotherapy 3. Patients having any uncontrolled co morbid conditions

Design outcomes

Primary

Measure	Time frame
1. To assess acute toxicity of extended field intensity modulated radiotherapy concurrent chemotherapy in patients of cervical cancer with PET positive pelvic lymph nodes.Timepoint: WEEKLY ASSESSMENT OF ACUTE TOXICITY DURING TREATMENT ASSESSMENT OF TOXICITY AFTER 6 WEEKS OF COMPLETE TREATMENT	—

Secondary

Measure	Time frame
late toxicity of treatmentTimepoint: 1 year post treatment	—

Countries

India

Contacts

Public ContactDr Nagarjun Ballari

PGIMER

Bhavana1035@gmail.com7087008391

Outcome results